Publication Date:
2010-11-19
Description:
Abstract 5082 Background: Prognosis for survival in mantle cell lymphoma (MCL) has recently been characterized using the MIPI algorithm. Using a retrospectively generated dataset of 150 patients with MCL seen at the H Lee Moffitt Cancer Center we sought to validate this approach in a more heterogeneous population. Methods: Patients were identified by physician survey, and through the use of our pathology and Total Cancer Care databases. Retrospective analysis was conducted with approval of our Institutional Review Board. In total 150 patients with MCL were identified, among whom MIPI data was available for 85 patients with a median followup of 36.8 months. Survival (expressed in months) was verified using our institutional records and the Social Security Death Index. Exploratory analysis of progression (n=79) and survival from the time of relapse (n=43) as stratified by MIPI were also conducted among evaluable patients. Data were compared using Kaplan-Meier survival analyses. Results: Median age was 65y (range 31–87), 73% male, 3% ECOG 〉1, 88% stage III/IV disease, 36% with extranodal involvement, and 38% with splenomegaly. Evaluation of the entire cohort shows median OS 57 (95% CI: 48, 70.9), median PFS 21.8 (95% CI: 14.2, 25.6), and median survival after relapse 27.6 (95% CI 25.4, 30.8). No benefit in OS was observed among patients receiving Cytarabine (HR 1.04, p=0.91) and/or Rituximab (HR 1.31, p=0.61) with initial chemotherapy. Relationship between PFS and survival after relapse demonstrated rho=0.51 (p
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine